Gaithersburg, MD, United States of America

Reinhard Ebner

This inventor holds 55 USPTO granted patents and 14 published patent applications and 1 EPO patent, primarily in Therapeutic Antibodies (CPC class C07K). Top assignees: Human Genome Sciences, Inc., Combimab, Inc.. Active years: 2001-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Reinhard Ebner. Retrieved from https://idiyas.com/inventor/reinhard-ebner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 55 (Patent Applications = 14)

% Patents Active = 54.5

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 4.5

ph-index = 16

Forward Citations = 616(Granted Patents)

Forward Citations (Not Self Cited) = 571(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Gatihersburg, MD (US) (2011)
Gaithersburg, MD (US) (2001 - 2014)

Company Filing History:

54 out of 676

Human Genome Sciences, Inc.

Years Active: 2001-2014

Loading Chart...

Areas of Expertise:

Neutrokine-alpha

Tumor Necrosis Factor

Therapeutic Peptides

Antibodies

Polypeptides

Human Growth Factors

B Lymphocytes

T-Cell Activity

Diagnostic Methods

Secreted Proteins

Immune Disorders

Apoptosis Inducing Molecule

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8748575 - Therapeutic peptides (2014-06-10),

2. 8303951 - Neutrokine-alpha antibodies and methods of use thereof (2012-11-06),

3. 8231873 - Methods of treatment using antibodies to Neutrokine-alpha (2012-07-31),

4. 8212004 - Neutrokine-alpha fusion proteins (2012-07-03),

5. 8173122 - Methods of treatment using antibodies to neutrokine-alpha (2012-05-08),

6. 8071092 - Methods of inhibiting B lymphocytes using antibodies to Neutrokine-alpha (2011-12-06),

7. 8003386 - Tumor necrosis factor receptors 6α and 6β (2011-08-23),

8. 7994284 - Connective tissue growth factor (CTGF-3) polypeptides (2011-08-09),

9. 7964190 - Methods and compositions for decreasing T-cell activity (2011-06-21),

10. 7737257 - Connective tissue growth factor (CTGF-3) (2010-06-15),

11. 7709218 - Tumor necrosis factor receptors 6α and 6β (2010-05-04),

12. 7611846 - Diagnostic methods involving human growth factor huXAG-1 (2009-11-03),

13. 7534428 - Antibodies to tumor necrosis factor receptors 6α and 6β (2009-05-19),

14. 7459531 - 50 Human secreted proteins (2008-12-02),

15. 7381800 - Antibodies to HBIMF63 polypeptide (2008-06-03),

Title: Reinhard Ebner: Pioneering Innovator in Biomedical Technologies

Introduction:

Reinhard Ebner is a distinguished inventor based in Gaithersburg, MD, with an impressive portfolio of 55 patents. His groundbreaking work in the field of biomedical technologies has significantly impacted the healthcare industry.

Latest Patents:

Ebner's latest patents include innovative solutions such as therapeutic peptides with guanylyl cyclase C agonist activity, which are instrumental in treating chronic ideopathic constipation, inflammatory bowel disease, and other related conditions. Additionally, his Neutrokine-alpha antibodies have opened new avenues in diagnosing and treating autoimmune disorders.

Career Highlights:

With a successful tenure at companies like Human Genome Sciences, Inc. and Combimab, Inc., Ebner has been at the forefront of cutting-edge research and development. His inventions have not only garnered recognition but have also contributed significantly to the advancement of medical science.

Collaborations:

During his career, Ebner has collaborated with esteemed professionals in the field, including individuals like Steven M. Ruben and Guo-Liang Yu. These collaborations have been instrumental in driving innovation and fostering a culture of excellence in biomedical research.

Conclusion:

Reinhard Ebner's unwavering dedication to innovation and his remarkable contributions to the field of biomedical technologies have solidified his reputation as a visionary inventor. His patents continue to shape the future of healthcare, offering new hope and possibilities for patients worldwide.Dot

Profile summary based on public USPTO records.